Novo Nordisk Company Description
Novo Nordisk can tell diabetics where to stick it. One of the world's leading producers of insulin, Novo Nordisk also makes insulin analogues, injection devices, and diabetes education materials. Its products include analogues Levemir and NovoLog (which mimic natural insulin regulation more closely than human insulin) and the FlexPen, a pre-filled insulin injection tool. In addition to its diabetes portfolio, the firm has products in the areas of hemostasis management (blood clotting), human growth hormone, and hormone replacement therapy. The not-for-profit Novo Nordisk Foundation, through its Novo A/S subsidiary, controls more than two-thirds of the voting power in Novo Nordisk.
View the Comprehensive Company Description for Novo Nordisk
The Company Description provides a historical perspective of Novo Nordisk's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Novo Nordisk's evolution in the marketplace.
